You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Quelling the Vicious Vortex: Targeting Neutrophil Serine Proteases in Non-Cystic Fibrosis Bronchiectasis: A Clinical Forum®

  • Authors: Doreen J. Addrizzo-Harris, MD, FCCP; Stefano Aliberti, MD; Pieter C. Goeminne, MD, PhD
  • CME Released: 11/2/2023
  • Valid for credit through: 11/1/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - Maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

Pulmonology, primary care, and radiology clinicians who manage patients with non-cystic fibrosis bronchiectasis (NCFBE).

The goal of this activity is to raise awareness of the symptoms and burden of non-cystic fibrosis bronchiectasis (NCFBE), as well as new treatment targets. Diagnostic delay leads to a cycle of frequent exacerbations during which the vicious vortex of neutrophil-mediated inflammation and lung damage occurs. New research is providing insights on the pathophysiology of NCFBE, including the role of neutrophilic inflammation and activation of neutrophil serine proteases (NSPs) by mediators, such as dipeptidyl peptidase 1 (DPP-1). Novel treatment approaches for inhibiting DPP-1 in NCFBE offer the potential for improving quality of life and preserving lung function.

Upon completion of this activity, participants should be better able to:

  • Identify the burden of non-cystic fibrosis bronchiectasis (NCFBE) and its exacerbations on patient quality of life
  • Utilize clinical practice guidelines to facilitate early NCFBE recognition and diagnosis
  • Assess the potential impact of targeting neutrophil serine protease (NSP) activation on the treatment of NCFBE


RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty Affiliation and Disclosures

  • Doreen J. Addrizzo-Harris, MD, FCCP

    Professor, Medicine
    Associate Director, Clinical and Academic Affairs
    Co-Director, NYU Bronchiectasis/NTM Clinical and Translational Program
    NYU Grossman School of Medicine
    New York, United States


    Doreen J. Addrizzo-Harris, MD, FCCP, has relevant financial relationships with AN2 Therapeutics, Boehringer Ingelheim, Hill-Rom, Insmed, Zambon (Grant/Research Support).

  • Stefano Aliberti, MD

    Professor, Respiratory Diseases
    Humanitas University
    Chief, Respiratory Unit
    IRCCS Humanitas Research Hospital
    Milan, Italy


    Stefano Aliberti, MD, has relevant financial relationships with AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited, GlaxoSmithKline S.p.A, Insmed, Insmed Ireland Limited, Insmed Italy S.R.L, Physio-Assist (Consultant); BRAHMS GmbH, Chiesi Farmaceutici S.p.A, Fondazione Internazionale Menarini, GlaxoSmithKline S.p.A, Insmed Ireland Limited, Insmed Italy S.R.L (Speaker/Speaker’s Bureau).

  • Pieter C. Goeminne, MD, PhD

    Staff Member, Department of Respiratory Disease
    VITAZ Hospital
    Saint-Nicholas, Belgium


    Pieter C. Goeminne, MD, PhD, has relevant financial relationships with Boehringer Ingelheim (Advisor); Merck (Consultant); Chiesi USA, Inc. (Grant/Research Support); Insmed (Speaker/Speaker’s Bureau).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Accreditation Statements

Interprofessional Continuing Education

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

To claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee for this educational activity.


Quelling the Vicious Vortex: Targeting Neutrophil Serine Proteases in Non-Cystic Fibrosis Bronchiectasis: A Clinical Forum®

Authors: Doreen J. Addrizzo-Harris, MD, FCCP; Stefano Aliberti, MD; Pieter C. Goeminne, MD, PhDFaculty and Disclosures

CME Released: 11/2/2023

Valid for credit through: 11/1/2024, 11:59 PM EST


Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print